MedTrace Logo

Conditioning, the Placebo Effect, and Psoriasis

NCT00005922 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2013-09-24

No results posted yet for this study

Summary

This study uses the psychological principle known as classical conditioning to try to improve the standard treatment of psoriasis. Classical conditioning is a process of behavioral modification in which a person learns to connect a certain response-in this case, improvement of psoriasis-with a new action, or stimulus-in this case, application of an inactive cream. The goal of this study is to show that people with psoriasis who are maintained on corticosteroid cream part of the time and an inactive (placebo) cream at other times show a lower incidence of relapse and a reduced severity of psoriasis that patients treated with that same (reduced) amount of medication administered all the time.

Conditions

Interventions

BEHAVIORAL

Partial schedule of pharmacotherapeutic reinforcement

Dose of 0.1% of Aristocort A on 1-2 of every 4 days for a period of up to 14 weeks.

DRUG

Dose control for Arm B

Dose of 0.025-0.05% of Aristocort A 2 times per day for a period of up to 14 weeks.

OTHER

Standard pharmacotherapeutic protocol

Full dose of Aristicort A (0.1%) 2 times per day for a period of up to 14 weeks.

Sponsors & Collaborators

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

    collaborator NIH

  • University of Rochester

    lead OTHER

Principal Investigators

  • Robert Ader, PhD · University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2000-08-31
Primary Completion
2006-07-31
Completion
2006-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005922 on ClinicalTrials.gov